Glucagon prescribing and prevention of hospitalization for hypoglycemia in a large health system.

Herges, Joseph R; Haag, Jordan D; Kosloski Tarpenning, Kimberly A; Mara, Kristin C; McCoy, Rozalina G

Herges, Joseph R; Haag, Jordan D; Kosloski Tarpenning, Kimberly A; Mara, Kristin C; McCoy, Rozalina G.

Afiliación

Herges JR; Department of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Herges.Joseph@mayo.edu.
Haag JD; Department of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Haag.Jordan@mayo.edu.
Kosloski Tarpenning KA; Department of Pharmacy, Mayo Clinic Health System, Southeast Minnesota region, Owatonna, MN, United States. Electronic address: Tarpenning.Kimberly@mayo.edu.
Mara KC; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States. Electronic address: Mara.Kristin@mayo.edu.
McCoy RG; Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, MN, United States. Electronic address: McCoy.Rozalina@mayo.edu.

Diabetes Res Clin Pract ; 202: 110832, 2023 Aug.

Article en En | MEDLINE | ID: mdl-37453512

Asunto(s)

Diabetes Mellitus Tipo 2; Hipoglucemia; Adulto; Humanos; Femenino; Glucagón/uso terapéutico; Diabetes Mellitus Tipo 2/complicaciones; Hipoglucemiantes/uso terapéutico; Estudios Retrospectivos; Hipoglucemia/tratamiento farmacológico; Hipoglucemia/epidemiología; Hipoglucemia/prevención & control; Hospitalización

Palabras clave

Diabetes; Glucagon; Hospitalization; Hypoglycemia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Hipoglucemia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Diabetes Res Clin Pract Asunto de la revista: ENDOCRINOLOGIA Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google